- 作者：Antonio Micari ; MD ; PhD? ; antoniomicari@tiscali.it ; Angelo Cioppa ; MD&dagger ; ; Giuseppe Vadalà ; MD? ; Fausto Castriota ; MD&Dagger ; ; Armando Liso ; MD§ ; ; Alfredo Marchese ; MD¡Î ; Chiara Grattoni ; MD&Dagger ; ; Paolo Pantaleo ; MD¶ ; ; Alberto Cremonesi ; MD&Dagger ; ; Paolo Rubino ; MD&dagger ; ; Giancarlo Biamino ; MD ; PhD&dagger ;
- 关键词：angioplasty ; drug-eluting balloon ; percutaneous transluminal angioplasty ; peripheral artery disease
- 刊名：JACC: Cardiovascular Interventions
- 出版年：2013
- 出版时间：March, 2013
- 年：2013
- 卷：6
- 期：3
- 页码：282-289
- 全文大小：1232 K
Objectives
This study aimed to appraise 2-year outcomes after percutaneous treatment of femoropopliteal artery disease with paclitaxel-eluting balloons.Background
Percutaneous transluminal angioplasty with paclitaxel-eluting balloons for femoropopliteal artery disease has provided favorable 1-year results.
Methods
Consecutive patients with Rutherford class 2 to 4 disease due to femoropopliteal lesions ¡Ü15 mm long and with 3- to 7-mm reference vessel diameter were prospectively enrolled in a multicenter registry. Endpoints of interest included primary patency, major adverse events (the composite of death, amputation, or target lesion revascularization), changes in Rutherford class, ankle-brachial index, absolute claudication distance, and quality of life after ¡Ý24 months.
Results
A total of 105 patients (114 lesions) treated with paclitaxel-eluting balloons and provisional stenting were enrolled, and final procedural success was obtained in all. Follow-up after 27 ¡À 3 months was obtained in 98 (93.3 % ) patients, showing that primary patency was maintained in 71 (72.4 % ), and major adverse events had occurred in 17 (17.5 % ), with persistently significant benefits in Rutherford class, ankle-brachial index, absolute claudication distance, and quality of life (all p < 0.001). Secondary patency rate was achieved in 89 cases (84.7 % ).
Conclusions
PEBs are associated with favorable functional and clinical outcomes at 2 years in patients with femoropopliteal artery disease requiring percutaneous revascularization.